An exploration of the effect of Chinese herbal compound on the occurrence and development of large intestine cancer and intestinal flora.

16S rRNA AOM/DSS-Induced colorectal cancer mice Chinese herbal compound Inflammation Large intestine cancer

Journal

Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560

Informations de publication

Date de publication:
15 Jan 2024
Historique:
received: 30 05 2023
revised: 05 12 2023
accepted: 05 12 2023
medline: 4 1 2024
pubmed: 4 1 2024
entrez: 4 1 2024
Statut: epublish

Résumé

This study was conducted to observe the effect of Chinese herbal compound on the treatment of colon cancer using AOM/DSS-induced C57BL/6J colon cancer mice and to validate potential influence on intestinal flora of mice. A colorectal cancer (CRC) mouse model was built with a total of 50 C57BL/6J mice that were induced by administrating AOM/DSS. These experimental animals were split up into 5 groups, a control group, a model group, and low-, medium- and high-dose Chinese herbal compound groups. All mice were given Chinese herbal compound treatment, and the colon tissues of each group were harvested with the length measured and the number of colon polyps accounted. The Ki-67 expression in the colon tissues was detected via immuno-histochemistry. Relative quantification of the expression of genes and proteins was determined through qPCR and WB assays. Contents of IL-6, TNF-α, IFN-γ, and IL-10 in serum and colon tissues of mice were determined by ELISA. An additional 16S rRNA sequencing analysis was implemented for the identification of mouse intestinal flora. The results suggested that all low-, medium- or high-dose Chinese herbal compound could markedly inhibit the shortening of colon length and significant number reduction of colon polyps in the model group. The relative expression of genes and proteins (PCNA, Muc16, and MMP-9) associated with proliferation in mouse colon tissues were inhibited. In addition, compared with the model group, the contents of IL-6, TNF-α, and IFN-γ in serum and colon tissues were substantially decreased in the high-dose Chinese herbal compound group, thereby reducing the structure damage in colon tissues and the infiltration degree of inflammatory cells. Besides, the expression of TLR4/MyD88/NF-κB protein was markedly decreased. The 16S rRNA sequencing analysis demonstrated that mice in the model group had decreased intestinal flora diversity, and there were significant changes in flora abundance and amino acid metabolism between the control group and the model group. Taken together, the treatment of Chinese herbal compound against CRC in this study might be regulated by the TLR4/MyD88/NF-κB signaling pathway, and the imbalance in intestinal flora was also closely related to CRC occurrence.

Identifiants

pubmed: 38173486
doi: 10.1016/j.heliyon.2023.e23533
pii: S2405-8440(23)10741-9
pmc: PMC10761579
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e23533

Informations de copyright

© 2023 Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Pingyu Liu (P)

Hunan University of Chinese Medicine, Changsha, 410208, Hunan, China.

Jian Ying (J)

Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China.

Xin Guo (X)

Hunan University of Chinese Medicine, Changsha, 410208, Hunan, China.

Xiaohui Tang (X)

Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China.

Wenjuan Zou (W)

Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China.

Tiantian Wang (T)

Department of Emergency Intensive Care, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China.

Xinyi Xu (X)

Hunan University of Chinese Medicine, Changsha, 410208, Hunan, China.

Bin Zhao (B)

Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China.

Na Song (N)

Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China.

Jun Cheng (J)

Department of Oncology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing, 400021, China.

Classifications MeSH